

PDX Data Sheet for COG-N-624x

Disease: Neuroblastoma
Phase of Therapy: Post-Chemotherapy (Progressive Disease)
Treatment: ANBL00B1 (Chemotherapy, Surgery)
Disease Stage: 4
Gender: Female
Age at diagnosis: 30 months
Race: NA
Age at sample collection: 41.6 months
Source of culture: Bone Marrow (2nd) January 2016
Primary tumor site: Posterior mediastinum
Date Established: May 2016

MYCN Patient: NA
MYCN PDX: Relative copy number – 2 copies
TH mRNA: Expressed
p53 functionality: NA
Telomere Mechanism: TERT+, C-circle negative
ALK: Wild Type

PDX RNAseq: Available upon request
PDX WES: Available upon request
Strain of Mice: NSG or Athymic NuNu (recommended)
Injection Type: Subcutaneous
Growth Properties: 15e6 cells minimum, ~3-5 months to 1500mm³
Please see Protocols section at
<https://www.cccells.org/protocols.php>

Human vs. Mouse: This PDX model has been tested and confirmed over multiple passages to be above 97% human cells.

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: NA

h-IMPACT Profile I IDEXX: PCR evaluation of EBV, HAAdV, Hantaan, HCMV, Hepatitis A, Hepatitis B, Hepatitis C, HHV 6, HHV8, HIV1, HIV2, HSV 1, HSV 2, HTLV 1, HTLV2, LCMV, Mycoplasma sp., Seoul, Sin Nombre, VZV were all negative.

PDX Data Sheet for COG-N-624x

Cell Line Name: COG-N-624x

References:



PDX Data Sheet for COG-N-624x

PDX Name: COG-N-624x

H&E slides